Study accepted for publication in Frontiers in Oncology highlights advantages in predicting breast cancer recurrence, particularly among younger patients
[by Yu, Suin] GENCURIX announced on April 15 that its breast cancer prognostic test, GenesWell 슬롯사이트 추천 (Breast Cancer Test), has demonstrated superior accuracy in predicting recurrence risk compared to leading international genetic assays. The results, recently accepted for publication in the renowned peer-reviewed journal Frontiers in Oncology, underline the test’s enhanced prognostic performance—particularly among breast cancer patients under the age of 50.
The study, titled “Additional prognostic value of the 슬롯사이트 추천 score in ER+HER2- breast cancer patients receiving a 21-gene assay guided adjuvant treatments,” involved a multicenter cohort of 759 breast cancer patients in South Korea. Researchers compared the prognostic performance of GenesWell 슬롯사이트 추천 against a globally recognized 21-gene recurrence score. The findings revealed that GenesWell 슬롯사이트 추천 not only demonstrated better overall prognostic capability but also provided meaningful stratification even among patients classified as low-risk by other tests.
Notably, the study highlighted a key clinical gap: younger breast cancer patients (under 50) with intermediate recurrence scores from standard tests were more effectively stratified using GenesWell 슬롯사이트 추천. “A low recurrence score from other assays doesn’t necessarily indicate low actual risk,” researchers explained. “GenesWell 슬롯사이트 추천 can offer more precise therapeutic guidance for younger patients, supporting personalized treatment decisions.”
Professor Sung Kwe Ahn, breast surgeon at Gangnam Severance Hospital and lead author of the study, stated, “This study offers compelling evidence that GenesWell 슬롯사이트 추천 can more precisely identify recurrence risks in patients with ambiguous results from other tests. It has the potential to become an essential tool for risk stratification in early-stage breast cancer.”
Hanjin Il, Executive Director at GENCURIX, added, “These findings are especially relevant for younger patients considering whether to omit chemotherapy after surgery. GenesWell 슬롯사이트 추천 provides them with critical insights to make more informed decisions.”
GenesWell 슬롯사이트 추천 is the only breast cancer prognostic test in Korea that has received regulatory approval from the Ministry of Food and Drug Safety and is covered by private health insurance. It is widely adopted in leading hospitals across the country and is currently being offered in several Asian countries, including Thailand.